NICE (UK National Institute for Clinical Excellence) consults on ECT (electroconvulsive therapy) recommendations:
This article was originally published in Clinica
Executive Summary
The National Institute for Clinical Excellence (NICE) has issued the final appraisal determination on the clinical and cost effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania. Subject to any appeal, NICE plans to recommend a limited use of the technique to achieve rapid and short-term improvement of severe symptoms, after other options have proven ineffective and/or when the condition is life-threatening, in cases of severe depressive illness, catatonia and a prolonged or severe manic episode. In the UK, the therapy is also currently used occasionally in the treatment of schizophrenia. The appeal period ends on December 23 2002.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.